{"id":"https://openalex.org/W3208795804","doi":"https://doi.org/10.3390/pharmaceutics13111821","title":"Infliximab Efficacy May Be Linked to Full TNF-\u03b1 Blockade in Peripheral Compartment\u2014A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model","display_name":"Infliximab Efficacy May Be Linked to Full TNF-\u03b1 Blockade in Peripheral Compartment\u2014A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model","publication_year":2021,"publication_date":"2021-11-01","ids":{"openalex":"https://openalex.org/W3208795804","doi":"https://doi.org/10.3390/pharmaceutics13111821","mag":"3208795804","pmid":"https://pubmed.ncbi.nlm.nih.gov/34834236","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8623740"},"language":"en","primary_location":{"id":"doi:10.3390/pharmaceutics13111821","doi":"https://doi.org/10.3390/pharmaceutics13111821","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics13111821","pdf_url":"https://www.mdpi.com/1999-4923/13/11/1821/pdf?version=1635770082","source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.mdpi.com/1999-4923/13/11/1821/pdf?version=1635770082","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5033266569","display_name":"David Ternant","orcid":"https://orcid.org/0000-0003-4020-4545","observed_orcids":["https://orcid.org/0000-0003-4020-4545"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"David Ternant","raw_affiliation_strings":["Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France"],"raw_orcid":"https://orcid.org/0000-0003-4020-4545","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France","institution_ids":["https://openalex.org/I110017253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068755879","display_name":"Olivier Le Tilly","orcid":"https://orcid.org/0000-0001-9308-4933","observed_orcids":["https://orcid.org/0000-0001-9308-4933"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Olivier Le Tilly","raw_affiliation_strings":["Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France","institution_ids":["https://openalex.org/I110017253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055568274","display_name":"Laurence Picon","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Laurence Picon","raw_affiliation_strings":["Department of Gastroenterology, CHRU de Tours, 37044 Tour, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Gastroenterology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003950598","display_name":"Driffa Moussata","orcid":"https://orcid.org/0000-0002-3631-1404","observed_orcids":["https://orcid.org/0000-0002-3631-1404","https://orcid.org/0009-0009-9434-4755"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Driffa Moussata","raw_affiliation_strings":["Department of Gastroenterology, CHRU de Tours, 37044 Tour, France","EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Gastroenterology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France","institution_ids":["https://openalex.org/I110017253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073706980","display_name":"Christophe Passot","orcid":"https://orcid.org/0000-0002-2634-2450","observed_orcids":["https://orcid.org/0000-0002-2634-2450"]},"institutions":[{"id":"https://openalex.org/I4210106090","display_name":"Institut de Canc\u00e9rologie de l'Ouest","ror":"https://ror.org/01m6as704","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210106090"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christophe Passot","raw_affiliation_strings":["D\u00e9partement de Biopathologie, Institut de Canc\u00e9rologie de l\u2019Ouest, 49055 Angers, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"D\u00e9partement de Biopathologie, Institut de Canc\u00e9rologie de l\u2019Ouest, 49055 Angers, France","institution_ids":["https://openalex.org/I4210106090"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026143127","display_name":"Th\u00e9odora Bejan\u2010Angoulvant","orcid":"https://orcid.org/0000-0002-0018-9996","observed_orcids":["https://orcid.org/0000-0002-0018-9996"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Theodora Bejan-Angoulvant","raw_affiliation_strings":["Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France","institution_ids":["https://openalex.org/I110017253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000719977","display_name":"C\u00e9line Desvignes","orcid":"https://orcid.org/0000-0002-5102-5908","observed_orcids":["https://orcid.org/0000-0002-5102-5908"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"C\u00e9line Desvignes","raw_affiliation_strings":["Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France"],"raw_orcid":"https://orcid.org/0000-0002-5102-5908","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France","institution_ids":["https://openalex.org/I110017253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018062347","display_name":"Denis Mulleman","orcid":"https://orcid.org/0000-0003-4089-7513","observed_orcids":["https://orcid.org/0000-0003-4089-7513"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Denis Mulleman","raw_affiliation_strings":["Department of Rheumatology, CHRU de Tours, 37044 Tour, France","EA 7501 \u201cGroupe Innovation et Ciblage Cellulaire\u201d, Universit\u00e9 de Tours, 37044 Tour, France"],"raw_orcid":"https://orcid.org/0000-0003-4089-7513","affiliations":[{"raw_affiliation_string":"Department of Rheumatology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 7501 \u201cGroupe Innovation et Ciblage Cellulaire\u201d, Universit\u00e9 de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I110017253"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031211618","display_name":"Philippe Goupille","orcid":"https://orcid.org/0000-0002-8605-1567","observed_orcids":["https://orcid.org/0000-0002-8605-1567"]},"institutions":[{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Philippe Goupille","raw_affiliation_strings":["Department of Rheumatology, CHRU de Tours, 37044 Tour, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Rheumatology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039278929","display_name":"Gilles Paintaud","orcid":"https://orcid.org/0000-0003-0158-1356","observed_orcids":["https://orcid.org/0000-0003-0158-1356"]},"institutions":[{"id":"https://openalex.org/I110017253","display_name":"Universit\u00e9 de Tours","ror":"https://ror.org/02wwzvj46","country_code":"FR","type":"education","lineage":["https://openalex.org/I110017253"]},{"id":"https://openalex.org/I4210095477","display_name":"Centre Hospitalier Universitaire de Tours","ror":"https://ror.org/00jpq0w62","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210095477"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Gilles Paintaud","raw_affiliation_strings":["Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology, CHRU de Tours, 37044 Tour, France","institution_ids":["https://openalex.org/I4210095477"]},{"raw_affiliation_string":"EA 4245 \u201cTransplantation, Immunology, Inflammation\u201d, Universit\u00e9 de Tours, 37044 Tours, France","institution_ids":["https://openalex.org/I110017253"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5033266569"],"corresponding_institution_ids":["https://openalex.org/I110017253","https://openalex.org/I4210095477"],"apc_list":{"value":2200,"currency":"CHF","value_usd":2376},"apc_paid":{"value":2200,"currency":"CHF","value_usd":2376},"fwci":0.8809,"has_fulltext":true,"cited_by_count":12,"citation_normalized_percentile":{"value":0.71092621,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":97},"biblio":{"volume":"13","issue":"11","first_page":"1821","last_page":"1821"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.4372999966144562,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.4372999966144562,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.38920000195503235,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.05909999832510948,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/infliximab","display_name":"infliximab","score":1.0},{"id":"https://openalex.org/keywords/target-mediated-drug-disposition","display_name":"target-mediated drug disposition","score":0.9769999980926514},{"id":"https://openalex.org/keywords/tnf-alpha-blockade","display_name":"TNF-alpha blockade","score":0.7149999737739563},{"id":"https://openalex.org/keywords/inflammatory-bowel-disease","display_name":"inflammatory bowel disease","score":0.7350000143051147},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7509999871253967},{"id":"https://openalex.org/keywords/two-compartment-model","display_name":"two-compartment model","score":0.7250000238418579},{"id":"https://openalex.org/keywords/therapeutic-drug-monitoring","display_name":"therapeutic drug monitoring","score":0.6449999809265137},{"id":"https://openalex.org/keywords/ankylosing-spondylitis","display_name":"ankylosing spondylitis","score":0.8619999885559082},{"id":"https://openalex.org/keywords/quasi-steady-state-approximation","display_name":"quasi-steady-state approximation","score":0.7850000262260437},{"id":"https://openalex.org/keywords/population-pharmacokinetic-model","display_name":"population pharmacokinetic model","score":0.746999979019165}],"concepts":[{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.8712183833122253},{"id":"https://openalex.org/C46762472","wikidata":"https://www.wikidata.org/wiki/Q178648","display_name":"Peripheral","level":2,"score":0.6907933950424194},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5783860683441162},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.578241229057312},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5711738467216492},{"id":"https://openalex.org/C203635412","wikidata":"https://www.wikidata.org/wiki/Q17007432","display_name":"Compartment (ship)","level":2,"score":0.48116764426231384},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4452965557575226},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.42818740010261536},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.424807608127594},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.4158720076084137},{"id":"https://openalex.org/C2777402515","wikidata":"https://www.wikidata.org/wiki/Q52849","display_name":"Ankylosing spondylitis","level":2,"score":0.414841890335083},{"id":"https://openalex.org/C17991360","wikidata":"https://www.wikidata.org/wiki/Q21173843","display_name":"Tumor necrosis factor alpha","level":2,"score":0.36296018958091736},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3344283103942871},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.282880961894989},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2803923487663269},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.22944989800453186},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C111368507","wikidata":"https://www.wikidata.org/wiki/Q43518","display_name":"Oceanography","level":1,"score":0.0},{"id":"https://openalex.org/C127313418","wikidata":"https://www.wikidata.org/wiki/Q1069","display_name":"Geology","level":0,"score":0.0}],"mesh":[],"locations_count":4,"locations":[{"id":"doi:10.3390/pharmaceutics13111821","doi":"https://doi.org/10.3390/pharmaceutics13111821","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics13111821","pdf_url":"https://www.mdpi.com/1999-4923/13/11/1821/pdf?version=1635770082","source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},{"id":"pmid:34834236","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34834236","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8623740","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8623740/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:e2d78037197449f6a4091c5a92ae7319","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/e2d78037197449f6a4091c5a92ae7319","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmaceutics, Vol 13, Iss 11, p 1821 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3390/pharmaceutics13111821","doi":"https://doi.org/10.3390/pharmaceutics13111821","is_oa":true,"landing_page_url":"https://doi.org/10.3390/pharmaceutics13111821","pdf_url":"https://www.mdpi.com/1999-4923/13/11/1821/pdf?version=1635770082","source":{"id":"https://openalex.org/S30283931","display_name":"Pharmaceutics","issn_l":"1999-4923","issn":["1999-4923"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310310987","host_organization_name":"Multidisciplinary Digital Publishing Institute","host_organization_lineage":["https://openalex.org/P4310310987"],"host_organization_lineage_names":["Multidisciplinary Digital Publishing Institute"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmaceutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9763000011444092,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1688735659","display_name":"Optimization of therapeutic monoclonal antibodies development Better antibodies, better developed AND better used","funder_award_id":"ANR-10-LABX-0053","funder_id":"https://openalex.org/F4320320883","funder_display_name":"Agence Nationale de la Recherche"}],"funders":[{"id":"https://openalex.org/F4320320883","display_name":"Agence Nationale de la Recherche","ror":"https://ror.org/00rbzpz17"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3208795804.pdf","grobid_xml":"https://content.openalex.org/works/W3208795804.grobid-xml"},"referenced_works_count":43,"referenced_works":["https://openalex.org/W28215347","https://openalex.org/W1537282756","https://openalex.org/W1566149917","https://openalex.org/W1849982557","https://openalex.org/W1889350102","https://openalex.org/W1892124695","https://openalex.org/W1927686514","https://openalex.org/W1989693988","https://openalex.org/W1997113562","https://openalex.org/W2000320798","https://openalex.org/W2009735641","https://openalex.org/W2010463972","https://openalex.org/W2016540556","https://openalex.org/W2028092295","https://openalex.org/W2038285281","https://openalex.org/W2040401921","https://openalex.org/W2054739927","https://openalex.org/W2097892506","https://openalex.org/W2106621962","https://openalex.org/W2118872783","https://openalex.org/W2152245204","https://openalex.org/W2283729348","https://openalex.org/W2417102977","https://openalex.org/W2463320065","https://openalex.org/W2512170617","https://openalex.org/W2514004462","https://openalex.org/W2600926306","https://openalex.org/W2610764164","https://openalex.org/W2760163217","https://openalex.org/W2773624951","https://openalex.org/W2790432738","https://openalex.org/W2791302651","https://openalex.org/W2803686345","https://openalex.org/W2955532968","https://openalex.org/W2971768893","https://openalex.org/W3011085857","https://openalex.org/W3033146225","https://openalex.org/W3038280503","https://openalex.org/W3108729245","https://openalex.org/W3113400896","https://openalex.org/W3192567839","https://openalex.org/W3192935299","https://openalex.org/W4232396212"],"related_works":["https://openalex.org/W3192567839","https://openalex.org/W2971768893","https://openalex.org/W6999714632","https://openalex.org/W2794508275","https://openalex.org/W1989693988","https://openalex.org/W7128676833","https://openalex.org/W7125165630","https://openalex.org/W2782782475","https://openalex.org/W2960185068","https://openalex.org/W2016540556"],"abstract_inverted_index":{"Infliximab":[0],"is":[1],"an":[2,18],"anti-TNF-\u03b1":[3],"monoclonal":[4],"antibody":[5],"approved":[6],"in":[7,25,50,151,155,184],"chronic":[8],"inflammatory":[9],"bowel":[10],"diseases":[11],"(IBD).":[12],"This":[13,139,158,171],"study":[14,159],"aimed":[15],"at":[16,34],"providing":[17],"in-depth":[19],"description":[20],"of":[21,62,93,128,144,164,169,182],"infliximab":[22,33,183],"target-mediated":[23,46,167],"pharmacokinetics":[24,168],"133":[26],"IBD":[27,185],"patients":[28,66],"treated":[29],"with":[30,44],"5":[31],"mg/kg":[32],"weeks":[35],"0,":[36],"2,":[37],"14,":[38],"and":[39,53,76,95,107,119,124,134,146],"22.":[40],"A":[41],"two-compartment":[42],"model":[43,140,172],"double":[45],"drug":[47,180],"disposition":[48],"(TMDD)":[49],"both":[51],"central":[52,94,156],"peripheral":[54,96,152],"compartments":[55,97],"was":[56],"developed,":[57],"using":[58,87],"a":[59,68,161],"rich":[60],"database":[61],"26":[63],"ankylosing":[64],"spondylitis":[65],"as":[67],"reference":[69],"for":[70],"linear":[71],"elimination":[72,126,149],"kinetics.":[73],"Population":[74],"approach":[75],"quasi-steady-state":[77],"(QSS)":[78],"approximation":[79],"were":[80,84,98],"used.":[81],"Concentration-time":[82],"data":[83],"satisfactorily":[85],"described":[86],"the":[88,165],"double-TMDD":[89],"model.":[90],"Target-mediated":[91],"parameters":[92],"respectively":[99],"baseline":[100],"TNF":[101],"concentrations":[102],"(RC0":[103],"=":[104,109,116,121,131,136],"3.3":[105],"nM":[106,118],"RP0":[108],"0.46":[110],"nM),":[111,123],"steady-stated":[112],"dissociation":[113],"rates":[114,127],"(KCSS":[115],"15.4":[117],"KPSS":[120],"0.49":[122],"first-order":[125],"complexes":[129],"(kCint":[130],"0.17":[132],"day\u22121":[133],"kPint":[135],"0.0079":[137],"day\u22121).":[138],"showed":[141],"slower":[142],"turnover":[143],"targets":[145],"infliximab-TNF":[147],"complex":[148],"rate":[150],"compartment":[153],"than":[154],"compartment.":[157],"allowed":[160],"better":[162],"understanding":[163],"multi-scale":[166],"infliximab.":[170],"could":[173],"be":[174],"useful":[175],"to":[176],"improve":[177],"model-based":[178],"therapeutic":[179],"monitoring":[181],"patients.":[186]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":1}],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2021-11-08T00:00:00"}